Pyroptosis is a type of acute cell death that mainly occurs in immune cells. It is characterized with robust release of inflammatory cytokines and has emerged to play a critical role in the pathogenesis of sepsis-associated immune disorders. In this study, we screened for pyroptotic inhibitors with the ultimate goal to benefit sepsis treatments. Accidentally, we identified nitrosonisoldipine (NTS), a photodegradation product of calcium channel inhibitor nisoldipine, blocking non-canonical pyroptosis. Using murine immortalized bone-marrow derived macrophage and human THP-1 cell line, we further discovered that NTS not only inhibits non-canonical pyroptosis mediated by caspase-11 or caspase-4, but also canonical pyroptosis mediated by caspase-1. Mechanistically, NTS directly inhibits the enzyme activities of these inflammatory caspases, and these inhibitory effects persist despite extensive washout of the drug. By contrast, apoptosis mediated by caspase-3/-7 was not affected by NTS. Mice pretreated with NTS intraperitoneally displayed improved survival rate and extended survival time in LPS- and polymicrobe-induced septic models respectively. In conclusion, NTS is a selective inhibitor of inflammatory caspases which blocks both the non-canonical and canonical pyroptotic pathways. It is safe for intraperitoneal administration and might be used as a prototype to develop drugs for sepsis treatments.
GrantsCollaborative Innovation of Industry, University, and Research Institute Major Program of Guangzhou Fundamental Research Funds for the Central Universities Natural Science Foundation of Jiangsu Province National Natural Science Foundation of China Ministry of Science and Technology of China